The multicenter, randomized trial is designed to estimate the efficacy of Livatag on overall survival in nearly 400 patients suffering from hepato cellular carcinoma, resistant or intolerant to sorafenib.
BioAlliance CEO Judith Greciet said, "The need for alternative therapeutics in primary advanced liver cancer is crucial and this trial should enable to establish the efficacy and the tolerance of Livatag® in this indication."
15 French sites professional in hepatology are initiated and able to start recruiting the first patients, the company said.
BioAlliance plans to expand the study to about 30 sites in France and abroad, in the short and middle term.